Literature DB >> 17908790

Ubiquitination and degradation of mutant p53.

Natalia Lukashchuk1, Karen H Vousden.   

Abstract

While wild-type p53 is normally a rapidly degraded protein, mutant forms of p53 are stabilized and accumulate to high levels in tumor cells. In this study, we show that mutant and wild-type p53 proteins are ubiquitinated and degraded through overlapping but distinct pathways. While Mdm2 can drive the degradation of both mutant and wild-type p53, our data suggest that the ability of Mdm2 to function as a ubiquitin ligase is less important in the degradation of mutant p53, which is heavily ubiquitinated in an Mdm2-independent manner. Our initial attempts to identify ubiquitin ligases that are responsible for the ubiquitination of mutant p53 have suggested a role for the chaperone-associated ubiquitin ligase CHIP (C terminus of Hsc70-interacting protein), although other unidentified ubiquitin ligases also appear to contribute. The contribution of Mdm2 to the degradation of mutant p53 may reflect the ability of Mdm2 to deliver the ubiquitinated mutant p53 to the proteasome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17908790      PMCID: PMC2169174          DOI: 10.1128/MCB.00050-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  69 in total

1.  Involvement of the DNA repair protein hHR23 in p53 degradation.

Authors:  Sandra Glockzin; Francois-Xavier Ogi; Arnd Hengstermann; Martin Scheffner; Christine Blattner
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

2.  Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation.

Authors:  Roger P Leng; Yunping Lin; Weili Ma; Hong Wu; Benedicte Lemmers; Stephen Chung; John M Parant; Guillermina Lozano; Razqallah Hakem; Samuel Benchimol
Journal:  Cell       Date:  2003-03-21       Impact factor: 41.582

Review 3.  The MDM2-p53 interaction.

Authors:  Ute M Moll; Oleksi Petrenko
Journal:  Mol Cancer Res       Date:  2003-12       Impact factor: 5.852

Review 4.  The p53-Mdm2 module and the ubiquitin system.

Authors:  Dan Michael; Moshe Oren
Journal:  Semin Cancer Biol       Date:  2003-02       Impact factor: 15.707

5.  A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.

Authors:  Chrystelle Brignone; Kathleen E Bradley; Alexei F Kisselev; Steven R Grossman
Journal:  Oncogene       Date:  2004-05-20       Impact factor: 9.867

6.  The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.

Authors:  Harumi Shimizu; Lindsay R Burch; Amanda J Smith; David Dornan; Maura Wallace; Kathryn L Ball; Ted R Hupp
Journal:  J Biol Chem       Date:  2002-03-29       Impact factor: 5.157

Review 7.  Tumor suppression by Ink4a-Arf: progress and puzzles.

Authors:  Scott W Lowe; Charles J Sherr
Journal:  Curr Opin Genet Dev       Date:  2003-02       Impact factor: 5.578

8.  Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53.

Authors:  Rajeev Rajendra; Diptee Malegaonkar; Pooja Pungaliya; Henderson Marshall; Zeshaan Rasheed; James Brownell; Leroy F Liu; Stuart Lutzker; Ahamed Saleem; Eric H Rubin
Journal:  J Biol Chem       Date:  2004-07-09       Impact factor: 5.157

9.  The ubiquitin ligase COP1 is a critical negative regulator of p53.

Authors:  David Dornan; Ingrid Wertz; Harumi Shimizu; David Arnott; Gretchen D Frantz; Patrick Dowd; Karen O'Rourke; Hartmut Koeppen; Vishva M Dixit
Journal:  Nature       Date:  2004-04-21       Impact factor: 49.962

10.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

View more
  107 in total

1.  SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.

Authors:  D Li; N D Marchenko; U M Moll
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

2.  Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53.

Authors:  Lorna Jane Warnock; Sally Anne Raines; Jo Milner
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

3.  Mdm2 facilitates the association of p53 with the proteasome.

Authors:  Roman Kulikov; Justine Letienne; Manjit Kaur; Steven R Grossman; Janine Arts; Christine Blattner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

4.  Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains.

Authors:  Chad A Corcoran; JoAnne Montalbano; Hong Sun; Qin He; Ying Huang; M Saeed Sheikh
Journal:  J Biol Chem       Date:  2009-05-29       Impact factor: 5.157

Review 5.  Protein quality control and degradation in cardiomyocytes.

Authors:  Xuejun Wang; Huabo Su; Mark J Ranek
Journal:  J Mol Cell Cardiol       Date:  2008-05-20       Impact factor: 5.000

6.  Ataxin-3 expression correlates with the clinicopathologic features of gastric cancer.

Authors:  Li-Xia Zeng; Yong Tang; Yun Ma
Journal:  Int J Clin Exp Med       Date:  2014-04-15

7.  Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.

Authors:  Sue Haupt; Catherine Mitchell; Vincent Corneille; Jake Shortt; Stephen Fox; Pier Paolo Pandolfi; Mireia Castillo-Martin; Dennis M Bonal; Carlos Cordon-Cardo; Guillermina Lozano; Ygal Haupt
Journal:  Cell Cycle       Date:  2013-05-08       Impact factor: 4.534

8.  The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.

Authors:  Saisai Wei; Hongbo Wang; Chunwan Lu; Sarah Malmut; Jianqiao Zhang; Shumei Ren; Guohua Yu; Wei Wang; Dale D Tang; Chunhong Yan
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

Review 9.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

10.  Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.

Authors:  Leixiang Yang; Tanjing Song; Qian Cheng; Lihong Chen; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2019-02-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.